2020年度胃癌治疗进展盘点  

Progress in the treatment of gastric cancer in 2020

作　　者：王雅坤[1] 沈琳[1] Wang Yakun;Shen Lin(Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所,消化肿瘤内科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《肿瘤综合治疗电子杂志》2021年第1期1-5,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家重点研发计划项目(2017YFC1308900)。

摘　　要：2020年,胃癌治疗领域取得了一定进展,总体来说治疗更加精准。围术期治疗方面,CLASS02研究结果显示对于Ⅰ期胃癌,由经验丰富的外科医生实施的腹腔镜全胃切除术联合淋巴结清扫与开腹全胃切除术的安全性相当。术前化疗联合抗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)治疗或抗血管生成治疗可以提高病理完全缓解率或R0切除率,但能否转化为患者的生存获益尚无明确证据。晚期胃癌治疗方面,进展主要体现在抗HER2治疗和免疫治疗两个方面。两个抗体药物偶联物(DS-8201和RC48)的阳性研究结果为二线及以上HER2阳性胃癌的治疗提供了更多选择。CheckMate-649研究和ATTRACTION-4研究结果肯定了免疫联合化疗在胃癌一线治疗中的作用,未来有望成为HER2阴性晚期胃癌一线治疗的标准模式。Some progress has been made in the field of gastric cancer treatment in 2020.Overall,treatment strategy became more precise.In the peri-operative treatment field,CLASS02 study indicated that for clinical stageⅠgastric cancer,the overall morbidity and mortality rates were similar between laparoscopic total gastrectomy group and open total gastrectomy group.In combination with anti-human epidermal growth factor receptor 2 or anti-vascular endothelial growth factor drugs could increase pathological complete response rate or R0 resection rate;however,survival benefit remains uncertain.For HER2-positive gastric cancer,the development of novel anti-HER2 drugs,including antibody-drug conjugates(DS-8201 and RC48),have provided more choices after progression with trastuzumab.The positive results of CheckMate-649 and ATTRACTION-4 have validated the value of adding immunotherapy in firstline treatment.Chemotherapy combining immunity therapy may become standard treatment for selected patients in the future.

关 键 词：腹腔镜全胃切除术 精准治疗 抗人表皮生长因子受体2药物 免疫治疗 

分 类 号：R735.2[医药卫生—肿瘤]